

MARCH 2006

CURRICULUM VITAE

Thomas French Whyne, Jr, MD, PhD
Gill Heart Institute
University of Kentucky
326 Wethington Building
900 South Limestone St.
Lexington, KY 40536-0284
(859) 323-5479

Date and Place of Birth:

August 25, 1937,
Ft. Leavenworth, Kansas

Marital Status:

Wife: Eugenia Ingram Whyne
b. February 10, 1940

Children: Thomas French Whyne, III
b. January 24, 1966

James Givens Whyne
b. March 21, 1968

Katherine Ingram Whyne
b. June 2, 1972

Education:

AB: University of Pennsylvania, 1959.
MD: University of Pennsylvania, 1963.
PhD: University of California at
San Francisco, 1970, (Biochemistry).

Medical Training:

Intern, Department of Medicine, The New York Hospital -
Cornell Medical Center,
July 1963 - June 1964.

Assistant Resident, Department of Medicine, The New York
Hospital - Cornell Medical Center,
July 1964 - June 1966.

U.S. Public Health Service Postdoctoral Research
Fellow, Cardiovascular Research Institute,
University of California Medical Center,
San Francisco, California,
July 1966 - June 1968.

American Heart Association Advanced Research
Fellow, Cardiovascular Research Institute,
University of California Medical Center,
San Francisco, California,
July 1968 - July 1969

CURRICULUM VITAE

Thomas French Whayne, Jr.

Page 2

Medical Training Continued:

**American Heart Association Advanced Research
Fellow, Banting and Best Department of Medical
Research, University of Toronto, Toronto,
Ontario, Canada
August 1969 - August 1970**

Professional Positions:

**Professor of Medicine
University of Kentucky
Division of Cardiovascular Medicine
April 1998 - present**

**Member, Division of Cardiology
Lexington Clinic,
August, 1977 – March 1998**

**Head, Division of Cardiology
Lexington Clinic,
Lexington, Kentucky,
1986 - 1988**

**Clinical Professor of Medicine
University of Kentucky,
Lexington, Kentucky
August 1977 – March 1998**

**Associate Member
Oklahoma Medical Research Foundation,
Oklahoma City, Oklahoma,
September 1972 - July 1977**

**Associate Professor of Medicine
The University of Oklahoma,
Oklahoma City, Oklahoma,
September 1972 - July 1977**

**Assistant Professor of Biochemistry and
Molecular Biology
The University of Oklahoma,
Oklahoma City, Oklahoma,
December 1972 - July 1977**

**Assistant Professor of Medicine
The Ohio State University,
Columbus, Ohio,
September 1970 - August 1972**

CURRICULUM VITAE

Thomas French Whayne, Jr.

Page 3

Military Service:

**Medical Corps, U.S. Army Reserve
1959 - 1972**

Honors and Awards:

**Phi Beta Kappa, University of
Pennsylvania, 1959.**

**Hoffman LaRoche Award, University of
Pennsylvania, School of Medicine,
1963.**

**Central Ohio Heart Association Research
Grant, 1970-1971.**

**Central Ohio Heart Association Research
Grant, 1971-1972.**

**Oklahoma Heart Association Research Grant,
1973-1974.**

**National Heart and Lung Institute Research
Grant No. HL 18178-01, awarded for
1975-1978.**

**Oklahoma Heart Association "Man of the Year"
Award, 1975-1976.**

**Sigma Delta Pi Spanish Honorary Society
University of Kentucky
Lexington, Kentucky
Honorary Inductee
April 23, 1998**

Who's Who in America, 58th Edition, 2003 to present.

Who's Who in the World, 22nd Edition, 2005 to present.

Guide to America's Top Physicians, 2004-2005 to present.

CURRICULUM VITAE

Thomas French Whayne, Jr.

Page 4

Committees:

**Member, American Heart Association
Southern Region Research Grant Review
Committee, 1975-1977**

**Chairman, Oklahoma Heart Association
Professional Education Committee,
1975-1977.**

**Multiple Committees, Lexington Clinic,
Lexington, Kentucky, 1977 - 1998**

**Multiple Committees, St. Joseph Hospital,
Lexington, Kentucky, 1977 – 1998**

**Heart Gala Co-Chairman, American Heart Assoc.--
Central Kentucky Division, 2003 (fund raising target
exceeded)**

Medical License:

Kentucky

CURRICULUM VITAE

Thomas French Whayne, Jr.

Page 5

Certification:

- 1. American Board of Internal Medicine, 1972.**
- 2. American Board of Internal Medicine,
Cardiovascular Disease, 1974.**

Societies and Associations:

- 1. Fellow, American College of Cardiology
1974 - present.**
- 2. Fellow, American College of Physicians
1973 - present**
- 3. Fellow, American Heart Association
Council on Arteriosclerosis,
1971 - present.**
- 4. Fellow, American Heart Association
Council on Clinical Cardiology,
1974 - present.**
- 5. Fellow, College of Physicians of
Philadelphia,
1979 - present.**
- 6. American Medical Association,
1973 - present.**
- 7. Kentucky State Medical Association,
1977 - present.**
- 8. Fayette County Medical Society,
1977 - present.**
- 9. American Heart Association,
Central Kentucky Division, Ohio Valley
Affiliate, Amer. Hrt. Assoc., 1977 - present.**
- 10. Kentucky Thoracic Society,
1977-1994.**
- 11. American Society of Echocardiography,
1977 – present.**
- 12. American Institute of Ultrasound in
Medicine, 1977-1987**

**Societies and
Associations - continued:**

- 13. American Federation for Clinical Research, 1967-1977.**
- 14. Central Society for Clinical Research, 1973-1977.**
- 15. Society of Sigma XI, 1976-1977.**
- 16. Undersea and Hyperbaric Medical Society, 1982-1994.**
- 17. Fellow, Colegio Interamericano de Medicos y Cirujanos, September 1991 – 2004.**
- 18. Member, American College of Physician Executives, 1992 - 1997.**
- 19. American Society of Nuclear Cardiology. 1994-1997.**
- 20. Miembro Correspondiente, Sociedad Mexicana de Cardiologia, June 1994 - present.**
- 21. Miembro Correspondiente, Sociedad Colombiana de Cardiología, November 1998 – present.**
- 22. Miembro Honorario, Sociedad Venezolana de Cardiología, July 1999—present.**
- 23. Socio Correspondiente, Sociedad Chilena de Cardiología y Cirugía Cardiovascular, December 2001—present.**
- 24. Miembro Honorario, Asociación Costarricense de Cardiología, August 2002—present.**
- 25. Miembro Correspondiente, Sociedad Peruana de Cardiología, May 2002—present.**
- 26. Fellow, International College of Angiology, August 2004—present.**
- 27. Miembro Honorario, Asociación Venezolana de Aterosclerosis, February 2005—present.**

CURRICULUM VITAE

Thomas French Whayne, Jr.

Page 7

**Hospital Staff Appointments,
Lexington, Kentucky:**

- 1. University of Kentucky Medical Center**
- 2. Veteran's Administration Hospital**
- 3. St. Joseph Hospital**
- 4. Central Baptist Hospital**
- 5. Samaritan Hospital: 1977-1998; Subsequently Emeritus**
- 6. St. Joseph East Hospital**

Service Clubs:

**The Rotary Club of Lexington, Kentucky,
July 1995 – present**

**University of Kentucky Fellows - Lexington, Kentucky
September 1997 - present**

Boards and Directorships:

**Board of Directors, Oklahoma Heart
Association, 1975-1977**

**Member, Board of Directors, Lexington Clinic,
Lexington, Kentucky, December 1991 - December 1994**

**Member, Board of Directors, Greater Lexington Division,
Ohio Valley Affiliate, American Heart Association,
June 1999 – present.**

**Board of Directors, Consortium for Southeastern
Hypertension Control (COSEHC), Wake Forest University
Medical Center, Winston Salem, NC, January 2000 –
present.**

**Chair (First Chair in history of COSEHC), Council of
Directors of the 20 COSEHC Cardiovascular Centers of
Excellence, Wake Forest University Medical Center, Winston
Salem, NC, 2003-2005.**

**Member, Institutional Review Board, University of
Kentucky, November 2003-present.**

**Co-Chairman, Membership Committee, International
College of Angiology, September 2004—present.**

Editorships:

**Editor Asociado—Extranjero, Revista Costarricense de
Cardiologia, 2002 – present.**

PUBLICATIONS: Thomas French Wayne, Jr.

Page 1

- 1. Jannetta PJ and Wayne TF Jr. Formaldehyde-treated, Regenerated Collagen Film and Film-laminate as a Substitute for Dura Mater. Surgical Forum 1965;16:435-437.**
- 2. Wayne TF Jr, Burkholder PM and Becker EL. Primary Amyloidosis. J. Chronic Dis 1966;19:1145-1156.**
- 3. Wayne TF Jr and Killip T III. Simulated Diving in man: Comparison of Facial Stimuli and Response in Arrhythmia. J. Appl Phys 1967;22:800-807.**
- 4. Smith NT, Eger EI II, Whitcher CE, Stoelting RK and Wayne TF Jr. The Circulatory Effects of the Addition of Nitrous Oxide to Halothane Anesthesia in Man. Anesthesiology 1968;29:212-213.**
- 5. Wayne TF Jr and Severinghaus JW. Experimental Hypoxic Pulmonary Edema in the Rat. J Appl Phys 1968;25:729-732.**
- 6. Wayne TF Jr, Felts JM and Harris PA. The Effect of Heparin on the Inactivation of Serum Lipoprotein Lipase by the Liver in Unanesthetized Dogs. J Clin Invest 1969;48:1246-1251.**
- 7. Wayne TF Jr and Felts JM. Activation of Lipoprotein Lipase: Comparative Study of Man and Other Mammals. Circulation Res 1970;26:545-551.**
- 8. Smith NT, Eger EI II, Stoelting RK, Wayne TF Jr, Cullen D and Kadis LB. The Cardiovascular and Sympathomimetic Responses to the Addition of Nitrous Oxide to Halothane in Man. Anesthesiology 1970;32:410-421.**
- 9. Wayne TF Jr. The Activation and Inactivation of Lipoprotein Lipase. PhD Dissertation, University of California, 1970;1-65.**
- 10. Wayne TF Jr and Felts JM. Activation of Lipoprotein Lipase. The Effects of Serum Lipoprotein Fractions and Heparin. Circulation Res 1970;27:941-951.**
- 11. Wayne, TF Jr, Smith NT, Eger EI II, Stoelting RK and Whitcher CE. The Effect of Halothane Anesthesia Reflex Cardiovascular Responses to Simulated Diving and the Valsalva Maneuver. Anesthesiology 1971;34:262-270.**
- 12. Wayne TF Jr. The Activation and Inactivation of Lipoprotein Lipase. Dissertation Abstracts 1971;32:No 5.**
- 13. Wayne TF Jr and Felts JM. Activation of Lipoprotein Lipase. An Evaluation of Calcium, Magnesium, and Ammonium as Cofactors. Circulation Res 1971;28:649-654.**
- 14. Wayne TF Jr and Felts JM. The Determination of Lipoprotein Lipase Activity: Effect of Different Albumin Preparations. Clin Biochem 1972;5:109-114.**
- 15. Wayne TF Jr, Smith NT, Eger EI II, Stoelting RK and Whitcher CE. Reflex Cardiovascular Responses to simulated diving. Angiology 1972;23:500-508.**

16. Whayne TF Jr and Witiak DT. A Comparative Study of the Inhibitory Activity of Clofibrate and Related Analogs on Lipoprotein Lipase in vitro. J Med Chem 1973;16:228-231.
17. Felts JM and Whayne TF Jr. A Small Oxygenator for Use with an Organ Perfusion System. IEEE Transactions on Biomedical Engineering 1973;20:382-384.
18. Whayne TF Jr. Effect of Heparin on the Kinetics of Guinea Pig and Human Post-heparin Lipase Activity. Proc Soc Exptl Biol Med 1974;145:595-603.
19. Leier CV, Schaal SF, Leighton RF and Whayne TF Jr. Heart Block in Alcoholic Cardiomyopathy. Arch Intern Med 1974;134:766-768.
20. Whayne TF Jr. Atherogenic Mechanisms. In: Pathophysiology, 2nd ed. (Frohlich ED, ed), Philadelphia, J.B. Lippincott Co.,1976.
21. Nakai T and Whayne TF Jr. Catabolism of Canine Apolipoprotein A-I: Purification, Catabolic Rate, Organs of Catabolism and the Liver Subcellular Catabolic site. J Lab Clin Med 1976;88:63-80.
22. Nakai T, Otto PS and Whayne TF Jr. Proteolysis of Canine Apolipoprotein by Acid Proteases in Canine Lysosomes. Biochem Biophys Acta 1976;422:380-389.
23. Nakai T, Whayne TF Jr and Tang J. The Amino and Carboxyl Terminal Sequences of Canine Apolipoprotein A-I. FEBS Lett 1976;64:409-411.
24. Nakai T, Otto PS, Kennedy DL and Whayne TF Jr. Rat High-density Lipoprotein Subfraction (HDL₃) Uptake and Catabolism by Isolated Rat Liver Parenchymal Cells. J Biol Chem 1976;251:4914-4921.
25. Ganesan D, Whayne TF Jr and Witiak DT: The Effect of Clofibrate and Analogs on Human Post-heparin Plasma Lipases. Artery 1976;2:467-479.
26. Whayne TF Jr and Morelli JF. Assays for Lipoprotein Lipase: Comparison of Radiolabeled versus Titration Method of Triolein versus Intralipid Substrate. Biochem Med 1977;17:248-257.
27. Chandraratna PAN, Littman BB, Serafini A, Whayne TF Jr and Robinson H. Echocardiographic Evaluation of Extracardiac Masses. Brit Hrt J 1978;40:741-749.
28. Imaizumi T, Chandraratna PAN, Whayne TF Jr, Schechter E and Bhatia SK. Transmural Myocardial Infarction with Prolapsing Mitral-leaflet Syndrome and Normal Coronary Arteries. Arch Intern Med 1978;138:1354-1355.
29. Yamada S, Otto PS, Kennedy DL and Whayne TF Jr. The Effects of Dexamethasone on Metabolic Activity of Hepatocytes in Primary Monolayer Culture. In Vitro 1980;16:559-570,.
30. Whayne TF Jr. The Hyperlipoproteinemias. J Fam Practice 1980;11:789-799.

PUBLICATIONS: Thomas French Whayne, Jr.

Page 3

31. Whayne TF Jr, Alaupovic P, Curry MD, Lee ET, Anderson PS and Schechter E. Plasma Apolipoprotein B and VLDL, LDL and HDL Cholesterol as Risk Factors in the Development of Coronary Artery Disease in Male Patients Examined by Angiography. *Atherosclerosis* 1981;39:411-424.
32. Whayne TF Jr. Letter to the editor: Management of Hyperlipoproteinemias. *J Fam Practice* 1981;12:815-816.
33. Whayne TF Jr. Catabolism of High Density lipoproteins. In: *High-Density Lipoproteins* (Day CE, ed), New York, Marcel Dekker, Inc., 1981;177-191.
34. Yamada S, Nakai T, Kutsumi Y, Takeda R, Kurakene K, Otto PS, Kennedy DL and Whayne TF Jr: Primary Monolayer Culture of Adult Rat Hepatocytes in a Serum Free System: Metabolic and morphological studies. *Biomed Res* 1981;2:491-500,1981.
35. Whayne TF Jr (Participant). Recruitment for Clinical Trials: The Lipid Research Clinics coronary primary prevention trial experience. *Circulation* 1981;66(Supp IV)76,78.
36. Whayne TF Jr (Participant). The Lipid Research Clinics Coronary Primary Prevention Trial Results: I. Reduction in incidence of coronary heart disease. *JAMA* 1984;251:351-364.
37. Whayne TF Jr (Participant): The Lipid Research Clinics Coronary Primary Prevention Trial Results: II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. *JAMA* 1984;251:365-374.
38. Whayne TF Jr (Participant): Gordon DJ et al, for the Lipid Research Clinic Program: High Density Lipoprotein Cholesterol and Coronary Heart Disease in Hypercholesterolemic Men: The Lipid Research Clinics coronary primary prevention trial. *Circulation* 1986;74:1217-1223.
39. Whayne TF Jr (Participant): Gordon DJ et al, for the Lipid Research Clinic Program: Seasonal Cholesterol Cycles: The Lipid Research Clinics Coronary Primary Prevention Trial Placebo Group. *Circulation* 76:1987;1224-1231.
40. Whayne TF Jr. Letter to the Editor: The Aspirin--Heart Study and the Journal's Embargo Policy. *NEJM* 1988;318:923.
41. Whayne TF Jr. Cholesterol--Myths and Facts. *55 Plus* 1989;1:No. 4:1.
42. Whayne TF Jr. Cholesterol: Get the Low-down on Your Level (interviewed article) *The Advantage Connection* 1995;1:No. 4:1 (Newsletter for Advantage Care).
43. Whayne TF Jr. Current Concepts of Aggressive Cholesterol Treatment. *Lexington Clinic Connection - Physician to Physician* 1996;1:1-2.
44. Whayne TF Jr. Women and Heart Disease: Lipid Perspective. *Lexington Clinic Connection--Physician to Physician* 1997;2:No. 1:4, Spring/Summer.
- ◆45. Whayne TF Jr. El Tratamiento Agresivo del Colesterol es Efectivo para Modificar la Aterosclerosis Coronaria. *Medico Interamericano* 1998;17:557-559.

PUBLICATIONS: Thomas French Whayne, Jr.

Page 4

- ◆46. Whayne TF Jr. El Tratamiento Agresivo del Colesterol es Efectivo para Modificar la Aterosclerosis Coronaria. *Revista Ecuatoriana de Cardiología* 1999; 7: 78-81.
- ◆47. Whayne TF Jr. El Paciente con Colesterol Elevado. *Revista de la Fundación Cordis, Resistencia, Argentina* 1999;2,No.2:7.
- 48. Whayne TF Jr and Zielke JC. Reduction of Cholesterol in Kentucky—a State at High Risk. *J Kentucky Med Assoc* 2000;98:248-253.
- 49. Whayne TF Jr and Zielke JC. Triglyceride Level: A Predictive Risk Factor for Atherosclerosis (letter to the editor). *Arch Int Med* 2001;161:295-296.
- ◆50. Whayne TF Jr. Summary of Conferences (in Spanish): Tratamiento Agresivo del Colesterol, Una Discusión de Problemas Difíciles de Lípidos, Nuevas Evidencias en el Manejo de la Hipertensión Arterial. *Revista Chilena de Cardiología* 2001;20:204-205.
- 51. Whayne TF Jr and Zielke JC. Problems With the New Adult Treatment Panel III Guidelines. *Preventive Cardiology* 2002;5:91.
- 52. Whayne TF Jr, Zielke JC, Dickson LG and Winters JL. State of the Art Treatment of the Most Difficult Low Density Lipoprotein (LDL) Cholesterol Problems: LDL Apheresis. *Journ Kentucky Med Assoc* 2002;100:535-538.
- 53. Whayne TF Jr and Zielke JC. Coronary Artery Disease Management in the Elderly. *Long-Term Care Interface* 2002;3:45-50.
- 54. Whayne TF Jr. CV Center Update. *COSEHC Heartbeats Newsletter* 2003;1,No.1:3.
- 55. Whayne TF Jr. Controversies in Clinical Trials. *COSEHC Heartbeats Newsletter* 2003;1,No.2:3.
- 56. Whayne TF Jr. How Low Should You Go?: Aggressive Lipid and Blood Pressure Treatments. *Medical News (Indiana, Kentucky, Ohio)* 2003;October:p11.
- 57. Zielke JC and Whayne TF Jr. Physical Fitness Considerations for Patients Who Use Wheelchairs. *Long-Term Care Interface* 2003;4:52-54.
- 58. Whayne TF Jr (Participant). Pfeffer MA et al for the Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction or Both. *N Engl J Med* 2003;349:1893-1906.
- 59. Whayne TF Jr. The Aggressive Treatment of Cholesterol in Men and Women, Including New and Alternative Approaches. *Medical News (Indiana, Kentucky, Ohio)* 2004;October: p11.
- ◆60. Whayne TF Jr. El Idioma Español: El Desafío y las Recompensas en la Vida Profesional y Personal de un Cardiólogo. University of Kentucky College of Arts and Sciences Dept. of Hispanic Studies Newsletter 2005;June:pp4-5.

PUBLICATIONS: Thomas French Whyne, Jr.
Page 5

- 61. Wright CM, Zielke JC and Whyne TF. Policosanol, an Aliphatic Alcohol Sugarcane Derivative: Use in Patients Intolerant of or Inadequately Responsive to Statin Therapy. Int J Angiology 2005;13:173-175.**
- ◆62. Whyne TF. Lipoproteínas de Baja Densidad (LDL), Marcadores de Trombosis, Inflamación, Disfunción Endotelial y sus Tratamientos. Boletín de la Asociación Venezolana de Aterosclerosis 2005;19;No.1:2-4.**
- 63. Whyne TF. Expert Answers (written interview on cholesterol and hypertension). Healthy Advice: Heart Attack and Stroke 2006;No.12:8.**

(◆Publications written and published in the Spanish language: total of 6)

PUBLICATIONS IN PRESS:

- *1. Whyne TF. Dislipidemias Atípicas y Refractarias al Tratamiento, in *Aterosclerosis al Día VI*, 6th ed, I Soltero (ed). Caracas, Venezuela, Asociación Venezolana de Aterosclerosis, 2005.**
- *2. Whyne TF. Lipoproteínas de Baja Densidad (LDL), Marcadores de Trombosis, Inflamación, Disfunción Endotelial y sus Tratamientos, in *Aterosclerosis al Día VI*, 6th ed, I Soltero (ed). Caracas, Venezuela, Asociación Venezolana de Aterosclerosis, 2005.**
- *3. Whyne TF. Riesgo Cardiovascular en Mujeres. *Revista Costarricense de Cardiología*. 2005;7(2).**
- 4. Whyne TF. Women and Cardiovascular Disease—Prevention of Heart Disease. *Int J Angiology*.**

(*Publications in press, written in the Spanish language)

ABSTRACTS: Thomas French Whayne, Jr.

Page 1

- 1. Whayne TF Jr and Killip T III. Diving Bradycardia in Man: Comparison of Different Facial Stimuli and Clinical Application. Circulation 1996;34 Supp No. III: 238. PRESENTED**
- 2. Sorensen SC, Severinghaus JW, Cruz J, Whayne TF Jr and Carcelen A. Respiratory Sensitivity to Hypoxia during and after Chronic Hypoxia. Fed Proc 1967;26:665. PRESENTED**
- 3. Whayne TF Jr and Severinghaus JW. Experimental Hypoxic Pulmonary Edema in the Rat. The Physiologist 1967;10:342. PRESENTED**
- 4. Whayne TF Jr, Felts JM and Harris PA. Inactivation of Serum Lipoprotein Lipase (LPL) by the Liver in Unanesthetized Dogs. Clinical Research 1968;16: 355. PRESENTED**
- 5. Whayne TF Jr and Felts JM. Comparative Mammalian Studies of Lipoprotein Lipase (LPL). Clinical Research 1969;17:125. PRESENTED**
- 6. Felts JM, Bezman-Tarcher A and Whayne TF Jr. The Effect of Ethanol on the Secretion of Very Low Density Lipoprotein (VLDL) from Livers of Fed and Fasted Rats. Clinical Research 1969;17:382. PRESENTED**
- 7. Whayne TF Jr and Felts JM. The Effect of Lipoprotein Preparations and Heparin on Lipoprotein Lipase Activation. Circulation 1970;42 Supp 3:6. PRESENTED**
- 8. Whayne TF Jr and Felts JM. A Study of the Calcium-dependent Activation of Lipoprotein Lipase (LPL). Clinical Research 1970;18:627. PRESENTED**
- 9. Little JA, Whayne TF Jr, Bhagwat AG, Buckley GC and Kallow A. A Case of Type I Hyperlipoproteinemia Unusually Sensitive to Dietary Alcohol and Fat with Induction of Lipemia. Clinical Research 1970;18:736. PRESENTED**
- 10. Felts JM and Whayne TF Jr. The Role of Heparin as a Possible Allosteric Modifier of Lipoprotein Lipase. J Amer Oil Chemists' Soc 1971;48:101 A. PRESENTED**
- 11. Whayne TF Jr and Felts JM. Activation of Lipoprotein Lipase: An Evaluation of Calcium as a Cofactor. J Amer Oil Chemists' Soc 1971;48:101 A. PRESENTED**

ABSTRACTS: Thomas French Whyne, Jr.

Page 2

12. Whyne TF Jr. The Effect of Heparin on the Kinetic Properties of Lipoprotein Lipase. *Circulation* 1971;44 Supp 2:27. **PRESENTED**
13. Whyne TF Jr. Metabolic Control of the Kinetic Properties of Lipoprotein Lipase. *J Lab Clin Med* 1971;44 (Abstracts):29. **PRESENTED**
14. Whyne TF Jr. Metabolic Control Mechanisms of Lipoprotein Lipase. *J Clin Invest* 1972;51:103 A. **PRESENTED**
15. Whyne TF Jr. Metabolic Control Mechanisms of Lipoprotein Lipase. Conference on Serum Lipoproteins, Graz, Austria, 1973 October 21-23. **PRESENTED**
16. Whyne TF Jr. Effect of Heparin on the Kinetics of Guinea Pig and Human Post-heparin Lipase Activity. In: *Atherosclerosis III. Proceedings of the Third International Symposium*, (Schettler G and Weizel A, eds) Springer-Verlag, New York, 1974;p. 883. **PRESENTED**
17. West KM, Bailey CP, Coniglione TC, Smith WO Jr, Scroggins KR, Ellison MG, Maxwell EL, Sanders ML and Whyne TF Jr. Diabetes in Nineteen Oklahoma Indian Tribes. *Diabetes* 1974;23: Supp 1:337.
18. Nakai T and Whyne TF Jr. The Subcellular Catabolic Site of Canine Apolipoprotein A in the Liver. *Clinical Research* 1974;22:651 A.
19. Nakai T and Whyne TF Jr. Catabolic Rate and Fate of Canine Apolipoprotein A. *Clinical Research* 1975;23:326 A.
20. Nakai T and Whyne TF Jr. Organs and Subcellular Sites Involved in Catabolism of Canine Apolipoprotein A. *Clinical Research* 1975;23:326 A. **PRESENTED**
21. Nakai T, Otto PS and Whyne TF Jr. Canine Apolipoprotein Degradation by Acid Proteases in Canine Liver Lysosomes. *Circulation* 1975;52, Supp II:40. **PRESENTED**
22. Nakai T and Whyne TF Jr. Rat Lipoprotein Uptake and Catabolism by Isolated Rat Liver Parenchymal Cells. *Federation Proc* 1976;35:1371. **PRESENTED**
23. Nakai T and Whyne TF Jr. Rat Lipoprotein Uptake and Catabolism by Isolated Rat Liver Parenchymal Cells. The IVth International Symposium on Atherosclerosis, Tokyo, Japan, 1976;August 24-28. Abstracts, p. 206. **PRESENTED**

ABSTRACTS: Thomas French Whyne, Jr.

Page 3

24. Nakai T and Whyne TF Jr. Cellular and Subcellular Site(s) of Canine Apolipoprotein A-I. The IVth International Symposium on Atherosclerosis, Tokyo, Japan, 1976;August 24-28. Abstracts p. 139. **PRESENTED**
25. Nakai T and Whyne TF Jr. Catabolic Rate and Fate of Canine Apolipoprotein A-I. The IVth International Symposium on Atherosclerosis, Tokyo, Japan, 1976;August 24-28. Abstracts, p. 138. **PRESENTED**
26. Whyne TF, Curry MD, Lee ET, Anderson PS, Alaupovic P and Schechter E. Risk Profile from Plasma Lipids and Plasma Apolipoprotein B in Angiographically Proven Coronary Atherosclerosis. AHA Council on Arteriosclerosis and American Society for the Study of Arteriosclerosis, 1976;November. Abstracts, p. 44.
27. Whitsett TL, Christensen HD, Whyne, TF Jr and Czerwinski. Metabolic Effects of Caffeine and Instant Coffee in Humans. Clin Res 1976;24:532A.
28. Abascal VM, Zielke Z, Mason JW and Whyne, TF. Increased Prevalence of Cardiovascular Risk Factors in a Rural Appalachian Area of Eastern Kentucky and Income Levels: The Coronary Valley Project. National Cardiovascular Health Conference, Washington, DC, 2002;April 11-13. Abstracts, p. 109, Poster No. 74. **PRESENTED**
29. Whyne TF. Women and Cardiovascular Disease—Prevention of Heart Disease. International J Angiology 2004;13:152. **PRESENTED**
30. Wright C, Zielke J and Whyne T. Alternative Lipid-Lowering Therapies: A Report of the Clinical Efficacy of Policosanol. Gill Heart Institute Cardiovascular Research Day, University of Kentucky, Lexington, 2004;October 25. Abstracts, p. 38. **PRESENTED**

INTERNATIONAL PRESENTATIONS GIVEN IN SPANISH: Thomas French Whyne, Jr
Page 1

- 1. Tratamiento del colesterol en pacientes con enfermedad coronaria. Presented to Medical Society, La Coruña, Spain, November 5, 1991.**
- 2. Tratamiento del colesterol en pacientes con enfermedad coronaria. Presented to Medical Society, Burgos, Spain, November, 7, 1991.**
- 3. Tratamiento de las dislipidemias. Presented to Instituto Nacional de Cardiología "Ignacio Chávez", Mexico City, Mexico, November, 10, 1992.**
- 4. Tratamiento de las dislipidemias en la enfermedad coronaria. Presented to Clínica la Luz, Madrid, Spain, April, 28, 1995.**
- 5. Problemas de cardiología, colesterol y la dieta de España. Impromptu presentation to the Madrid-Serrano Rotary Club, Madrid, Spain, September 15, 1997.**
- 6. Tratamiento agresivo del colesterol: fundamentos clínicos para la estabilización y control de la enfermedad coronaria. Simposio Internacional de Cardiología, Cartagena, Colombia, November 22-24, 1998.**
- 7. Tratamiento actualizado de la insuficiencia Cardíaca congestiva en el consultorio: aspectos prácticos para el cardiólogo. Simposio Interacional de Cardiología, Cartagena, Colombia, November 22-24, 1998.**
- 8. Live interview on radio (in Spanish) on risk reduction for coronary heart disease, Cartagena, Colombia, November 20, 1998.**
- 9. Tratamiento agresivo del colesterol: fundamentos clínicos para la estabilización y control de la enfermedad coronaria. Facultad de Medicina, La Universidad del Nordeste, Corrientes, Argentina, May 29, 1999; Conferencia de la Fundación Cordis, Resistencia, Argentina, May 29, 1999 and Sociedad Médica de la Provincia Chaco, Resistencia, Argentina, May 30, 1999.**
- 10. La importancia del tratamiento actualizado de la hipertensión. Hospital Público, Resistencia, Argentina, May 28, 1999 and Sociedad Médica de la Provincia Chaco, Resistencia, Argentina, May 30, 1999.**
- 11. Tratamiento actualizado de la insuficiencia cardíaca congestiva en el consultorio: aspectos prácticos para el médico. Sociedad Médica de la Provincia Chaco, Resistencia, Argentina, May 30, 1999.**
- 12. Interview on radio (in Spanish) on risk reduction for coronary heart disease, Resistencia, Argentina, May 29, 1999.**
- 13. Interview on television (in Spanish) on risk reduction for coronary heart disease, Resistencia, Argentina, May 29, 1999.**

- 14. Tratamiento actualizado de la insuficiencia cardíaca congestiva en el consultorio: aspectos-prácticos para el médico. Sociedad Venezolana de Cardiología, Margarita Island, July 28, 1999.**
- 15. Tratamiento agresivo del colesterol: fundamentos clínicos para la estabilización y control de la enfermedad coronaria. Sociedad Venezolana de Cardiología, Margarita Island, July 31, 1999.**
- 16. Tratamiento agresivo de las dislipidemias. Congreso Ecuatoriano de Cardiología, Quito, Ecuador, October 26, 1999.**
- 17. Mesa Redonda: Manejo Clínico de la Cardiopatía Isquémica Crónica. Congreso Ecuatoriano de Cardiología, Quito, Ecuador, October 26, 1999.**
- 18. Conferencia Magistral: Insuficiencia Cardíaca. Congreso Ecuatoriano de Cardiología, Quito, Ecuador, October 27, 1999.**
- 19. Comentarios por parte de todo los ponentes invitados internacionales. Congreso Ecuatoriano de Cardiología, Quito, Ecuador, October 27, 1999.**
- 20. Tratamiento agresivo de la hipercolesterolemia actualizada. Centre Cardiovascular Sant Jordi y Clínica Tres Torres, Barcelona, Spain, May 5, 2000.**
- 21. Últimos conceptos en el Tratamiento Agresivo del Colesterol. Sociedad Médica de La Paz, Bolivia, June 8, 2000.**
- 22. Tratamiento actual de la Insuficiencia Cardíaca en el Consultorio. Sociedad Médica de La Paz, Bolivia, June 8, 2000.**
- 23. Tratamiento Agresivo de la Hiperlipidemia. Primera Reunión Mexicana de Nefrología. Universidad Juarez del Estado de Durango, Durango, México, January 13, 2001.**
- 24. Tratamiento Agresivo del Colesterol. Hospital San Javier, Guadalajara, México, January 17, 2001.**
- 25. Actualización en Dyslipidemias. Congreso Dominicano de Cardiología, Santo Domingo, República Dominicana, August 4, 2001.**
- 26. Tratamiento Agresivo del Colesterol. Congreso Dominicano de Cardiología, Santo Domingo, República Dominicana, August 4, 2001.**
- 27. Panel y Discusión: Prevención de la Enfermedad Coronaria. Congreso Chileno de Cardiología y Cirugía Cardiovascular: Pucón, Chile, December 13, 2001.**

- 28. Tratamiento Agresivo del Colesterol. Congreso Chileno de Cardiología y Cirugía Cardiovascular, Pucón, Chile, December 14, 2001.**
- 29. Nuevas Evidencias en el manejo de la Hipertensión Arterial. Congreso Chileno de Cardiología y Cirugía Cardiovascular, Pucón, Chile, December 14, 2001.**
- 30. Manejo de la Insuficiencia Cardíaca en la Clínica Ambulatoria. Congreso Chileno de Cardiología y Cirugía Cardiovascular, Pucón, Chile, December 14, 2001.**
- 31. Una Discusión de Problemas Difíciles de Lípidos. Congreso Chileno de Cardiología y Cirugía Cardiovascular, Pucón, Chile, December 14, 2001.**
- 32. El Beneficio de Cardioprotección en el Paciente Hipertenso. Congreso Guatemateco de Cardiología, Guatemala City, Guatemala, August 6, 2002.**
- 33. El Tratamiento Actualizado de la Insuficiencia Cardíaca y Revisión del Papel de Beta Bloqueantes. Congreso Costarricense de Cardiología, San José, Costa Rica, August 8, 2002.**
- 34. El Beneficio de Cardioprotección en el Paciente Hipertenso. Congreso Costarricense de Cardiología, San Jose, Costa Rica, August 8, 2002.**
- 35. El Tratamiento Actualizado de la Insuficiencia Cardíaca y Revisión del Papel de Beta Bloqueantes. Conferencia de Médicos, Copán Ruinas, Honduras, August 10, 2002.**
- 36. El Beneficio de Cardioprotección en el Paciente Hipertenso. Conferencia de Médicos, Copán Ruinas, Honduras, August 10, 2002.**
- 37. Terapia Agresiva del Colesterol. Congreso Peruano de Cardiología, Lima, Perú, May 2, 2003.**
- 38. Últimos Estudios sobre la Hipertensión—Significado para el Cardiólogo y Médico General (Conferencia Magistral—Plenary Lecture). Congreso Peruano de Cardiología, Lima, Perú, May 2, 2003.**
- 39. Manejo de la Insuficiencia Cardíaca en la Clínica Ambulatoria. Congreso Peruano de Cardiología, Lima, Perú, May 3, 2003.**
- 40. El Tratamiento Actualizado del Colesterol y la Prevención de la Aterosclerosis. Segundo Congreso Internacional de Cardiología Invasiva de Guadalajara, Guadalajara, México, June 12, 2003.**

- 41. Dislipidemias Atípicas y Refractarias al Tratamiento. VII Simposium Venezolano—Internacional de Aterosclerosis, Caracas, Venezuela, February 11, 2005.**
- 42. EUROPA en el Continuum Cardiovascular: Intervención Sobre Marcadores de Trombosis, Inflamación y Disfunción Endotelial. VII Simposium Venezolano—Internacional de Aterosclerosis, Caracas, Venezuela, February 12, 2005.**
- 43. Nuevos Conceptos en el Tratamiento de la Hipertensión. XX Congreso Peruano de Cardiología, Lima, Perú, April 28, 2005.**
- 44. Nuevos Tratamientos del LDL Colesterol y de la Aterosclerosis. XX Congreso Peruano de Cardiología, Lima, Perú, April 30, 2005.**
- 45. Raras y Dificiles Dislipidemias. XX Congreso Peruano de Cardiología, Lima, Perú, April 30, 2005.**
- 46. La Enfermedad Coronaria. Magazine Interview for ASI (La Actualidad), from Miami. XX Congreso Peruano de Cardiología, Lima, Perú, April 30, 2005.**
- 47. El Tratamiento Actual de la Hipertensión y el Estudio ALLHAT. VIII Congreso Internacional Sociedad Latinoamericana de Aterosclerosis, Acapulco, México, September 23, 2005.**
- 48. Tratamiento Agresivo del Colesterol. VIII Congreso Internacional Sociedad Latinoamericana de Aterosclerosis, Acapulco, México, September 23, 2005.**
- 49. ESTUDIO EUROPA: Intervención Sobre Marcadores de Trombosis, Inflamación y Disfunción Endotelial. VIII Congreso Internacional Sociedad Latinoamericana de Aterosclerosis, Acapulco, México, September 23, 2005.**